Technical Analysis for KPRX - Kiora Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -3.15% | |
| MACD Bearish Centerline Cross | Bearish | -3.15% | |
| Stochastic Reached Oversold | Weakness | -3.15% | |
| Gapped Up | Strength | -3.15% | |
| Down 3 Days in a Row | Weakness | -3.15% | |
| Oversold Stochastic | Weakness | -3.15% |
| Alert | Time |
|---|---|
| Down 1 ATR | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| 3x Volume Pace | 1 day ago |
| Down 5% | 1 day ago |
| 2x Volume Pace | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 11/07/2024
Kiora Pharmaceuticals, Inc. Description
EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Disease Surgery Disorders Eye Surgery Hyaluronic Acid Lasik Refractive Surgery
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.982 |
| 52 Week Low | 3.0 |
| Average Volume | 27,786 |
| 200-Day Moving Average | 4.46 |
| 50-Day Moving Average | 3.52 |
| 20-Day Moving Average | 3.59 |
| 10-Day Moving Average | 3.53 |
| Average True Range | 0.23 |
| RSI (14) | 41.18 |
| ADX | 16.7 |
| +DI | 17.24 |
| -DI | 22.40 |
| Chandelier Exit (Long, 3 ATRs) | 3.46 |
| Chandelier Exit (Short, 3 ATRs) | 3.85 |
| Upper Bollinger Bands | 3.91 |
| Lower Bollinger Band | 3.28 |
| Percent B (%b) | 0.02 |
| BandWidth | 17.70 |
| MACD Line | -0.02 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0348 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.62 | ||||
| Resistance 3 (R3) | 3.61 | 3.50 | 3.57 | ||
| Resistance 2 (R2) | 3.50 | 3.41 | 3.50 | 3.55 | |
| Resistance 1 (R1) | 3.39 | 3.36 | 3.34 | 3.40 | 3.53 |
| Pivot Point | 3.28 | 3.28 | 3.25 | 3.28 | 3.28 |
| Support 1 (S1) | 3.17 | 3.19 | 3.12 | 3.18 | 3.05 |
| Support 2 (S2) | 3.06 | 3.14 | 3.06 | 3.03 | |
| Support 3 (S3) | 2.95 | 3.06 | 3.02 | ||
| Support 4 (S4) | 2.96 |
